G-Triglim 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The combination targets multiple pathophysiological defects of type 2 diabetes, providing complementary mechanisms to achieve better glycemic control. G-Triglim 2 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults when monotherapy is inadequate. The sustained-release formulation allows for once-daily dosing, improving patient compliance. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, liver function, and renal parameters is recommended during therapy. This combination should be used under medical supervision to minimize the risk of hypoglycemia and other adverse effects.